Application of Reelin protein in preparation of medicine for treating retinal injury

Through exogenous recombinant Reelin protein in retinal ischemia and reperfusion injury, cell apoptosis is inhibited through the Dab1-Pi3k/Akt pathway, solving the problem of retinal IR injury treatment, and achieving improvement of retinal damage and vision protection.

CN119033914AActive Publication Date: 2024-11-29THE THIRD MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410945559.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-29
Estimated Expiration
2044-07-15

AI Technical Summary

Technical Problem

Retinal ischemia and reperfusion injury leads to neuronal cell death, lack of effective treatment, and leads to vision loss. The prior art does not clarify the mechanism of the Reelin protein in retinal IR injury.

Method used

Exogenous recombinant Reelin protein is used to inhibit cell apoptosis through the Dab1-Pi3k/Akt pathway by improving retinal tissue morphological abnormalities, optic nerve cell death and dysfunction, as a therapeutic drug for retinal ischemia and reperfusion injury.

Benefits of technology

Through the application of Reelin protein, the tissue morphology after retinal injury is significantly improved and cell apoptosis is inhibited, providing a new treatment plan for retinal ischemia and reperfusion injury to delay or prevent vision loss.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033914A_ABST
    Figure CN119033914A_ABST
Patent Text Reader

Abstract

The invention provides an application of Reelin protein in preparation of a medicine for treating retinal injury, relates to the technical field of protein medicines, and applies the Reelin protein in preparation of the medicine for treating the retinal injury. The retinal ischemia-reperfusion injury process is adjusted by improving retinal tissue morphological abnormality after the retinal injury, retinal optic nerve cell death after the retinal injury, retinal dysfunction after the retinal injury and retinal cell apoptosis after the retinal injury. When the Reelin protein is used for preparing the medicine for treating the retinal injury, a basis can be provided for a novel medicine for treating the retinal ischemia-reperfusion injury.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of protein medicines, and in particular to an application of Reelin protein in the preparation of medicines for treating retinal damage. Background Art

[0002] Ischemia-reperfusion (IR) injury is a pathological change with high morbidity, high disability and high mortality. In addition to causing serious consequences in important organs such as the brain, heart and kidneys, it is also involved in a variety of retinal diseases. In the diagnosis and treatment of retinal IR injury, the main manifestation is the further aggravation of tissue damage after the restoration of retinal blood flow. In the absence of effective treatment, retinal IR injury will cause the gradual loss of neurons, leading to changes in retinal morphology and function, and ultimately leading to vision loss.

[0003] Retinal IR damage leads to a decrease in the oxygen and nutrient supply to retinal cells, which eventually causes oxidative stress, inflammation, immune response and calcium overload in the tissue, leading to neuronal cell death. Neuronal death includes apoptosis, ferroptosis and autophagy, among which apoptosis is considered to be one of the main mechanisms of retinal damage after IR damage, and is mainly completed through the mitochondria-mediated endogenous apoptosis pathway. Therefore, inhibiting the expression of related apoptotic proteins in this pathway will help prevent and treat retinal IR damage.

[0004] In humans and mice, the Reln gene encodes an extracellular macromolecular matrix glycoprotein, Reelin, which plays an important role in the mammalian central nervous system. However, it is not clear how Reelin plays a role in retinal IR injury and whether it can be used to treat retinal IR injury.

[0005] Therefore, the present invention proposes the use of an exogenous recombinant protein Reelin in the preparation of a drug for treating retinal ischemia-reperfusion injury to solve the above problems. Summary of the invention

[0006] The present invention provides an application of Reelin protein in preparing a drug for treating retinal damage, so as to solve the problem of how Reelin protein plays a role in retinal IR damage and whether it can be used to treat retinal IR damage.

[0007] In a first aspect of an embodiment of the present invention, a use of Reelin protein in preparing a drug for treating retinal damage is proposed.

[0008] In an optional embodiment of the present invention, the Reelin protein regulates the retinal ischemia-reperfusion injury process by improving abnormal retinal tissue morphology after retinal injury.

[0009] In an optional embodiment of the present invention, the Reelin protein regulates the retinal ischemia-reperfusion injury process by improving retinal optic nerve cell death after retinal injury.

[0010] In an optional embodiment of the present invention, the Reelin protein regulates the retinal ischemia-reperfusion injury process by improving retinal dysfunction after retinal injury.

[0011] In an optional embodiment of the present invention, the Reelin protein regulates the retinal ischemia-reperfusion injury process by improving retinal cell apoptosis after retinal injury.

[0012] In an optional embodiment of the present invention, the Reelin protein regulates the retinal ischemia-reperfusion injury process via the Dab1-Pi3k / Akt pathway.

[0013] In an optional embodiment of the present invention, the Reelin protein activates the Pi3k / Akt pathway to inhibit retinal cell apoptosis after injury by causing phosphorylation of the intracellular Dab1 protein.

[0014] In a second aspect of an embodiment of the present invention, a drug for treating retinal damage is provided, wherein the active ingredient of the drug is Reelin protein.

[0015] In an optional embodiment of the present invention, the drug further includes a pharmaceutically acceptable carrier, and the pharmaceutically acceptable carrier at least includes physiological saline or PBS.

[0016] In an optional embodiment of the present invention, the dosage range of the drug is 300ng / ul to 500ng / ul.

[0017] The present invention includes the following advantages: The embodiment of the present invention provides an application of Reelin protein in the preparation of a drug for treating retinal damage, and the Reelin protein is used in the preparation of a drug for treating retinal damage, and the retinal ischemia-reperfusion injury process is regulated by improving abnormal retinal tissue morphology after retinal damage, retinal optic nerve cell death after retinal damage, retinal dysfunction after retinal damage, and retinal cell apoptosis after retinal damage. Among them, the Reelin protein activates the Pi3k / Akt pathway to inhibit retinal cell apoptosis after damage by causing phosphorylation of Dab1 protein in cells. The use of Reelin protein in the preparation of a drug for treating retinal damage can provide a basis for a new drug for treating retinal ischemia-reperfusion injury. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings required for use in the description of the embodiments of the present invention will be briefly introduced below. Obviously, the accompanying drawings in the following description are only some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying creative labor.

[0019] Figure 1 is a schematic diagram of a mouse retinal IR injury model provided by an embodiment of the present invention;

[0020] Figure 2 This is a rendering of a retinal local Reln gene knockdown mouse model provided by an embodiment of the present invention;

[0021] Figure 3 This is a graph showing the expression results of the Reln gene in a retinal IR injury mouse model provided in an embodiment of the present invention;

[0022] Figure 4 This is a diagram showing the results of retinal tissue damage repair regulated by Reln gene provided by an embodiment of the present invention;

[0023] Figure 5 This is a result diagram of a retinal IR injury-induced Reln gene promoting post-IR cell apoptosis through the Dab1-Pi3k / Akt pathway provided by an embodiment of the present invention;

[0024] Figure 6 This is a diagram showing the results of Reelin protein promoting retinal tissue damage repair provided by an embodiment of the present invention;

[0025] Figure 7 This is a result diagram of Reelin protein inhibiting cell apoptosis through Dab1-Pi3k / Akt pathway after retinal IR injury provided by an embodiment of the present invention. DETAILED DESCRIPTION

[0026] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0027] Ischemia-reperfusion (IR) injury is a type of pathological change with high morbidity, high disability rate and high mortality rate. Its essence is tissue damage caused by inflammatory factors, inflammatory cells and oxygen free radicals on the basis of blood reperfusion of ischemic tissue. IR injury occurring in important organs such as the brain, heart and kidneys can lead to serious consequences, including stroke, myocardial infarction and acute kidney injury. IR injury is also involved in a variety of retinal diseases, such as retinal vascular occlusion, diabetic retinopathy, glaucoma and retinopathy of prematurity. Retinal IR injury is a common type of pathological injury process in clinical ophthalmology diagnosis and treatment, and is mainly manifested by further aggravation of tissue damage after retinal blood flow is restored. Due to the lack of effective treatment, retinal IR injury can cause gradual loss of neurons, changes in retinal morphology and function, and ultimately lead to vision loss. Therefore, the prevention and treatment of IR injury has always been a hot topic in the field of ophthalmology. Exploring the mechanism of retinal IR injury and studying effective prevention and treatment methods will provide new ideas for the prevention and treatment of retinal IR injury.

[0028] Retinal IR damage leads to reduced oxygen and nutrient supply to retinal cells, which eventually causes oxidative stress, inflammation, immune response and calcium overload in tissues, leading to neuronal cell death. Neuronal death can be triggered by different mechanisms, including apoptosis, ferroptosis and autophagy. Among them, apoptosis is considered to be one of the main mechanisms of retinal damage after IR damage, and it is mainly completed through the mitochondria-mediated endogenous apoptosis pathway. Therefore, inhibiting the expression of related apoptotic proteins in this pathway will help prevent and treat retinal IR damage.

[0029] In humans and mice, the Reln gene encodes an extracellular macromolecular matrix glycoprotein, Reelin, which plays an important role in the mammalian central nervous system. It regulates the radial migration of neurons and the maturation of dendrites and dendritic spines during embryonic development; it maintains synaptic plasticity and regulates neural signal transmission and synaptogenesis in adulthood. Recent research results show that the signal transduction and integration of Reelin protein in endothelial cells and neurons promotes communication between blood vessels, glial cells and neurons, and this integration is essential for the integrity of the mature retinal vascular barrier. As an extension of the central nervous system, reports on the Reln gene in the visual system are currently mainly concentrated in the retina. The expression of Reelin protein in the adult retina is mainly located in RGCs (Retinal ganglion cells) / RBCs (redblood cell life span, retinal bipolar cells). Studies have shown that the Reln signaling pathway is related to the maturation of excitatory and inhibitory synaptic mechanisms, which affect the development and fine-tuning of the retinal neural network during postnatal development. Related studies have shown that Reelin protein in the central nervous system can promote neuronal cell survival by inhibiting apoptosis and play a protective role in cerebral ischemia-reperfusion injury. However, how Reeln gene and Reelin protein play a role in retinal IR injury in mice and the related mechanism of action are still unknown.

[0030] Therefore, the present invention proposes the use of an exogenous recombinant protein Reelin in the preparation of a drug for treating retinal ischemia-reperfusion injury to solve the above problems.

[0031] In the first aspect of the embodiment of the present invention, a use of Reelin protein in the preparation of a drug for treating retinal damage is proposed. Among them, Reelin protein is a highly conserved extracellular matrix glycoprotein encoded by the Reln gene, which is an important regulator of neuronal migration and synaptogenesis. The Reln signaling pathway regulates the targeted projection of retinal ganglion cell (RGC) dendrites to central neurons. The exogenous recombinant protein reelin is an extracellular matrix protein that can be purchased through commercial channels.

[0032] Based on the application proposed in the first aspect above, the Reelin protein regulates the retinal ischemia-reperfusion injury process by improving the abnormal morphology of retinal tissue after retinal injury, the Reelin protein regulates the retinal ischemia-reperfusion injury process by improving the death of retinal optic nerve cells after retinal injury, the Reelin protein regulates the retinal ischemia-reperfusion injury process by improving retinal dysfunction after retinal injury, and the Reelin protein regulates the retinal ischemia-reperfusion injury process by improving retinal cell apoptosis after retinal injury, wherein ischemia-reperfusion injury is tissue damage caused by ischemia and is the main cause of fatal diseases, such as myocardial infarction and stroke caused by coronary artery sclerosis. In the rescue and treatment of ischemic diseases, the main factor causing damage to tissues is not ischemia itself, but after the blood supply is restored, excessive free radicals attack the cells in the tissue that regains blood supply. This damage is called "tissue ischemia-reperfusion injury".

[0033] Based on the application proposed in the first aspect above, the Reelin protein regulates the retinal ischemia-reperfusion injury process through the Dab1-Pi3k / Akt pathway. Specifically, the Reelin protein causes phosphorylation of the intracellular Dab1 protein to activate the Pi3k / Akt pathway to inhibit retinal cell apoptosis after injury.

[0034] In a second aspect, an embodiment of the present invention proposes a drug for treating retinal damage, wherein the active ingredient of the drug is Reelin protein, and the drug also includes a pharmaceutically acceptable carrier such as physiological saline or PBS. The drug can be administered by intravitreal injection, and the dosage range of the administration is 300ng / ul to 500ng / ul, and the dosage is obtained through experiments.

[0035] The embodiment of the present invention provides an application of Reelin protein in the preparation of a drug for treating retinal damage. The Reelin protein is used to prepare a drug for treating retinal damage, and the retinal ischemia-reperfusion injury process is regulated by improving abnormal retinal tissue morphology, retinal optic nerve cell death, retinal dysfunction and retinal cell apoptosis after retinal damage. The Reelin protein activates the Pi3k / Akt pathway to inhibit retinal cell apoptosis after damage by causing phosphorylation of Dab1 protein in cells. The use of Reelin protein in the preparation of a drug for treating retinal damage can provide a basis for a new drug for treating retinal ischemia-reperfusion injury.

[0036] Since Reelin protein can promote neuronal cell survival by inhibiting apoptosis in the central nervous system and play a protective role in cerebral ischemia-reperfusion injury, however, how the Reln gene plays a role in mouse retinal IR injury and the study of related mechanisms of action are still unknown. First, the present invention constructs a mouse model and verifies the mechanism of action of the Reln gene in mouse retinal IR injury.

[0037] Example 1: Construction and grouping of mouse models

[0038] A: Construction of retinal IR injury model

[0039] Mice were selected as the construction object of the retinal IR injury model. The above-mentioned mice used were healthy C57BL / 6J wild-type male mice of 6-8 weeks old and weighing 16-22g (purchased from Beijing Sibeifu Experimental Animal Technology Co., Ltd.). A No. 33 needle containing a balanced salt solution was inserted into the anterior chamber to maintain intraocular pressure (IOP) at 110mmHg for 60 minutes. The sham operation group as a control was performed without increasing intraocular pressure. After 60 minutes, IOP was restored to normal by carefully pulling out the needle. In order to prevent bacterial infection, tobramycin eye ointment (Alcon, the United States) was used to treat it. 3d and 7 days after IR injury, mice were over-anesthetized and their eyeballs were removed.

[0040] The specific operation of fluorescent staining of retinal flat mounts is as follows: 7 days after I / R injury, the eyeballs are collected as described above, the muscles and connective tissues at the back of the eyeballs and other eyeball accessory tissues are removed, and the eyeballs are fixed in 4% paraformaldehyde fixative for 3 hours. A puncture is made at the limbus of the cornea and sclera with a 15° ophthalmic surgical puncture knife under a stereomicroscope, and the cornea, iris, lens, and vitreous are removed from the puncture along the limbus of the cornea and sclera with micro spring scissors. The eye cup is radially and evenly cut with the optic nerve as the center to form 4 parts, and the sclera is placed on a glass slide with the sclera facing up. The optic nerve and the transition point between the sclera and the optic nerve are cut off to completely separate the retina from the uvea, and the residual pigment tissue on the sclera, uvea, and retina is removed. The separated retina is rinsed in 0.1% PBST (washing buffer) and then dehydrated with 50% and 100% methanol gradients. Goat serum is blocked at room temperature for 1 hour, and RBPMS Polyclonal After incubation at 4°C in the dark for 24 h, the retinas were washed with 0.1% PBST and incubated with Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody (A-11011, Thermo Fisher Scientific) at room temperature in the dark for 1 h. The retinas were spread on glass slides and sealed with anti-fluorescence quenching sealing agent containing DAPI (ab104139; Abcam). The images were taken and analyzed using a high-content imaging system (Operetta CLS, PerkinElmer, UK).

[0041] Optical coherence tomography of the retina is performed as follows:

[0042] The mice were fixed and anesthetized (15mL / kg 1% sodium pentobarbital + 20μl 10% sumenxin by intraperitoneal injection) and placed on a lifting platform. The compound tropicamide eye drops were used to dilate the pupil. After the ocular surface was anesthetized by oxybuprocaine hydrochloride eye drops, medical carbomer eye drops gel (Dr. Gerhard Mann, Chem.-Pharm. Fabrik GmbH, Germany) was applied to the cornea to be tested. The light source of the ophthalmic ultramicroscopic imaging system (OPTOPROBE, UK) was adjusted to focus, and the lens focus was adjusted to the retina for optical coherence tomography. Then, the total retinal thickness (from the inner limiting membrane to the retinal pigment epithelium) was analyzed using the software (version 2.0) of OptoProbe Research Ltd. Four points were randomly selected within 200 to 300 microns from the outside of the optic disc for measurement and the average value was taken.

[0043] The retinal IR injury model constructed is referred to Figure 1 , Figure 1A schematic diagram of a mouse retinal IR injury model provided in an embodiment of the present invention, Figure 1 Part A in the middle is a representative picture of 33G needle injection in the anterior chamber of the mouse model before and after IR injury. Figure 1 Part B in the middle is a fundus photograph showing the retina damaged by IR. It can be seen that after IR damage, the retinal blood vessels of the mouse are intermittently supplied with blood, the peripheral retina is atrophied, and the choroid is visible. Figure 1 Part C in the middle is a representative fluorescent staining image of the retinal flat mount before and after IR injury, showing the distribution of RBPMS (RNA binding protein with multiple splicing, a marker that can be used for RGC quantification in various RGC degeneration models) positive RGCs (see the orange mark in the figure), and the number of RGCs is significantly reduced. Figure 1 Part D in the middle is an OCT (Optical Coherence Tomography) scan of the retina after IR injury. It can be seen that the retina of the mouse is significantly thinned after IR injury (Ctrl in the figure is the control group).

[0044] B: Construction of a mouse model with local retinal Reln gene knockdown

[0045] Adeno-associated virus (AAV-2 / 9-shRNA-Reln, HANBIO, China) was used to locally knock down the expression of the mouse retinal Reln gene. The above mice were healthy C57BL / 6J wild-type male / female mice aged 6-8 weeks and weighing 16-22g (purchased from Beijing Sibeifu Laboratory Animal Technology Co., Ltd.). Three weeks before the start of modeling, adeno-associated virus (AAV) solution loaded with specific targets (2μL, 1.0×10 12 vg / ml) was injected into the vitreous to establish a mouse model of retinal local Reln gene knockdown. AAV virus carries enhanced green fluorescent protein (EGFP), and the target sequence of siRNA of Reln gene is CCAGGATACATGATGCAATTT.

[0046] See also Figure 2 , Figure 2 This is a diagram showing the effect of a retinal local Reln gene knockdown mouse model provided by an embodiment of the present invention. Figure 2 Part A in the middle shows the retinal infection effect of the mouse model 3 weeks after AAV was passed through the vitreous cavity. The green part in the figure is the EGFP that comes with AAV, and the scale bar is 40 microns. Figure 2Part B is the expression result of Reln mRNA. NC is the blank control group, AAV-EGFP is the AAV virus carrying enhanced green fluorescent protein labeling group, and AAV-Reln is the adeno-associated virus local knockdown of mouse retinal Reln genome. It can be seen that the expression of Reln gene in AAV-Reln group is significantly lower than that in NC group and AAV-EGFP group. Therefore, the expression of Reln gene in mice can be locally knocked down by adeno-associated virus AAV-2 / 9-shRNA-Reln, and the mouse model of local retinal Reln gene knockdown is successfully constructed.

[0047] The specific operation of intravitreal injection is as follows:

[0048] After the mice were anesthetized, the pupils were dilated for 5 minutes with compound tropicamide eye drops (Santen Pharmaceutical Co., Ltd, Japan). A 34G microsyringe (Hamilton, Switzerland) was used to collect accurate 2 μl of exogenous recombinant mouse Reelin protein, PBS, AAV-shReln and AAV-EGFP, and then slowly pierced the eyeball from the superior temporal quadrant (about 1 mm from the edge of the cornea and sclera), and the needle tip was directed toward the optic disc to avoid puncturing the lens. It can be clearly seen from the dilated pupil that the needle tip is located in the vitreous cavity, and the drug is slowly pushed in until all the drug is pushed in, and the needle tip is pulled out to complete the injection.

[0049] C: Experimental Grouping

[0050] The experimental mice were divided into two groups: Reelin protein group and Reln gene knockdown group. Among them, mice in the Reelin protein group were randomly injected with 2ul exogenous recombinant mouse Reelin protein (300ng / μL, R&D Systems, USA) and 2ul PBS into the vitreous cavity 24h before modeling. The mice were divided into the Reelin group and the PBS group, and the retinal IR injury model was constructed. The mice after modeling were divided into the Reelin-IR group and the PBS-IR group. Mice in the Reln gene knockdown group were randomly injected with 2ul AAV-shReln and AAV-EGFP into the vitreous cavity 3 weeks before modeling. The mice were divided into the AAV-shReln group and the AAV-EGFP group, and the retinal IR injury model was constructed. The mice after modeling were divided into the AAV-shReln-IR group and the AAV-EGFP-IR group.

[0051] Example 2: Expression of Reln gene after retinal IR injury

[0052] The Reln-CreERT2 mTmG mouse was used to study the expression of the Reln gene in retinal homeostasis and after IR injury. The mTmG mouse is a genetic mouse that is red all over. The frozen sections and confocal microscopy of the eyeball samples of the mouse revealed that the EGFP signal of Reln-positive cells was expressed in the inner granular layer, inner plexiform layer and ganglion cell layer of the retina.

[0053] Immunofluorescence staining was performed as follows: mouse eyeballs were fixed in 4% paraformaldehyde overnight, dehydrated with graded sucrose solution, embedded in OCT embedding medium and quickly frozen in liquid nitrogen. Retinal cryosections of 5 μm thickness through the optic nerve plane were permeabilized with 0.3% Triton X-100 (solarbio, China) solution, blocked with goat serum for 1 hour and incubated with primary antibody overnight. The primary antibody was Reelin Polyclonal Antibody (1:500, Thermo, USA), followed by incubation with Alexa Fluor 488-conjugated secondary antibody (Thermo Fisher Scientific, MA, USA) at room temperature for 2 hours. The slides were sealed with anti-fluorescence quenching sealing agent containing DAPI (ab104139; abcam, UK). Images were taken using an Olympus VS200 virtual slide scanning microscope (Olympus, Japan).

[0054] See also Figure 3 , Figure 3 This is a graph showing the expression results of the Reln gene in a retinal IR injury mouse model provided in an embodiment of the present invention (Ctrl and Control in the figure are both control groups), Figure 3 Part A in the middle shows the results of Reln-CreERT2 mTmG mice expressing Reln-positive cells and their progeny at different time points after retinal IR injury. Figure 3 Part B in the middle is a representative image of Reelin immunofluorescence staining at different time points after IR injury in the retina of wild-type mice. Figure 3 Parts C and D in the middle are the statistical results of the percentage of Reln-positive cells in the retina and the intensity of Reelin immunofluorescence. Figure 3Part E in the middle is the expression result of Reln mRNA after retinal IR injury. It can be seen that after retinal IR injury, Reln expression first decreased and then increased, but it was still lower than the expression level of the normal control group. The scale bar is 40 microns, and the data are expressed as mean ± standard deviation (n = 6). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

[0055] According to the fluorescence images of frozen sections of Reln-CreERT2 mTmG mice at different time points after IR injury, the EGFP fluorescence signal in the 24h group after IR injury began to gradually weaken, and this trend reached the lowest point 7 days after IR injury. After that, the EGFP fluorescence signal began to gradually increase until 28 days after injury, but it was still lower than the control group level (see Figure 3 Part A and Part C, P < 0.05). The results of Reelin immunofluorescence staining in wild-type mice were completely consistent with the above results (see Figure 3 In addition, the inventors used qRT-PCR to determine the mRNA expression of Reln gene in retinal IR injury, and the results showed that the level of Reln gene decreased significantly 24h and 3 days after IR injury, and the level of Reln gene in the retina gradually increased 7 days, 14 days and 28 days after IR injury, but was still lower than the control group level (see Figure 3 The above results showed that the level of Reln gene decreased rapidly in the short term after retinal IR injury, indicating that Reln gene may participate in the injury regulation process in IR injury and play an important role.

[0056] Example 3: Reln gene regulates retinal tissue damage and repair

[0057] In order to verify the regulatory role of the Reln gene in the IR injury process, it is first necessary to construct a Reln gene knockdown mouse. However, due to the full mutation of the Reln gene in mice (reeler mice), they usually die 1-2 weeks after birth, and the whole body tissue morphology changes, including cerebellar hypoplasia, cerebral cortex and hippocampal neuron layer structural disorder. Therefore, this example chooses to successfully establish a retinal Reln gene knockdown mouse model by intravitreal injection of AAV 3 weeks before modeling. The retina was HE stained 7 days after IR injury modeling, and the thickness of the inner retina was measured and counted.

[0058] The specific operation is as follows: 7 days after I / R injury, the eyeballs were collected as described above and immediately immersed in 4% PFA (Polyfluoroalkoxy, soluble polytetrafluoroethylene) overnight and embedded in paraffin. Five-micron thick sections cut through the optic nerve were stained with hematoxylin and eosin (H&E) to observe the structural changes of the retina. In order to quantify retinal damage, 4 points were randomly selected for each eyeball to measure the thickness of the inner retinal layer (the inner retina extends from the inner limiting membrane to the inner edge of the outer plexiform layer) in the range of 200 to 300 microns outside the optic disc, and the data were averaged. Images were taken with an optical microscope (Olympus).

[0059] The results can be found in Figure 4 , Figure 4 This is a diagram showing the results of Reln gene regulation of retinal tissue damage repair provided in this embodiment. Figure 4 Part A in the middle is the result of HE staining retinal tissue pathology. Figure 4 Part B in the middle is a representative OCT image of retinal tissue changes after IR injury 7 days later. Figure 4 Part C in the middle is a representative fluorescence staining result of the retinal flat mount 7 days after IR injury. Figure 4 Part D in the middle is a representative oscillatory potential waveform of visual function assessed by FERG 7 days after IR injury. Figure 4 Part E in the middle is a quantitative image of the inner retinal layer thickness (n=6). Figure 4 Part F in the middle is the quantitative result of total retinal thickness (n=6). Figure 4 Part G in the middle shows the number of RBPMS-positive RGCs (n=4). Figure 4 The middle H part is the quantitative results of a-wave and b-wave amplitude (n=6), the scale bars are 20 μm, 100 μm or 1 mm, respectively, and the data are expressed as mean ± standard deviation, *P<0.05, ***P<0.001.

[0060] It can be seen that the thickness of the inner retina of mice was significantly thinner after injury, and the thickness of the inner retina of Reln gene knockdown mice was further reduced after injury compared with the negative control group (see Figure 4 Part A and Part E, P < 0.05). Similarly, the inventors used OCT to evaluate the dynamic in vivo retinal tissue, and the results showed that the thickness of the retinal full layer of Reln gene knockdown mice after injury was further reduced (see Figure 4 The results of immunofluorescence staining of mouse retina showed that the RGC density in the AAV-shReln-IR group was significantly lower than that in the AAV-EGFP-IR group, and the RGC count in the whole retina was also significantly reduced (see Figure 4C and G, P < 0.05). The retinal thickness and RGC number of the undamaged AAV-shReln group were slightly lower than those of the AAV-EGFP group, but there was no statistical difference. Afterwards, the inventors evaluated the visual function by flash electroretinogram (FERG). The results showed that compared with the AAV-EGFP-IR group, the amplitude of the retinal a-wave or b-wave of the AAV-shReln-IR group was significantly reduced. In addition, the amplitude of the retinal a-wave or b-wave of the undamaged AAV-shReln group was also lower than that of the AAV-EGFP group, and there was a statistical difference (see Figure 4 Part D and H in the middle, P < 0.05). AAV-shReln-mediated local knockdown of the Reln gene aggravated the symptoms of IR-injured mice, mainly manifested in thinning of the retinal thickness, reduction in the number of RGC cells, and retinal dysfunction. This shows that the Reln gene can regulate retinal homeostasis and damage repair. After knocking down the retinal Reln gene, retinal IR damage was further aggravated.

[0061] Example 4: Reln gene knockdown promotes cell apoptosis via the Dab1-Pi3k / Akt pathway

[0062] As described in Examples 2 and 3, knockdown of the Reln gene promoted the death of mouse retinal RGCs after IR injury. To clarify the mechanism of action of the Reln gene in mouse retinal IR injury, the effect of local knockdown of the Reln gene on cell apoptosis was evaluated by TUNEL staining.

[0063] The specific operation is as follows: 3 days after I / R injury, the eyeballs were collected as described above, and the retinal frozen sections were stained using the TUNEL kit (C1090 Beyotime, Jiangsu, China). The cells were fixed with 4% PFA for 30 minutes. PBS was washed for 20 minutes, and the membrane was permeabilized with 0.5% Triton X-100 at room temperature for 5 minutes. TUNEL detection solution (TDT enzyme + fluorescent labeling solution) was added to the sample and incubated at 37°C in the dark for 60 minutes. The slides were sealed with an anti-fluorescence quenching sealing agent containing DAPI. Images were taken using an Olympus VS200 virtual slide scanning microscope (Olympus).

[0064] The results refer to Figure 5 , Figure 5 This is a result diagram of a retinal IR injury-induced Reln gene promoting post-IR cell apoptosis through the Dab1-Pi3k / Akt pathway provided by an embodiment of the present invention, Figure 5 Part A in the middle is a representative TUNEL staining image of the frozen section of the retina of AAV-shReln mice 3 days after IR injury. Figure 5Part B in the middle is the quantitative result of TUNEL-positive cells (n=6). Figure 5 Part C in the middle is a representative blot showing the effects of local knockdown of Reln on retinal Dab1, p-Dab1, Pi3k, Akt, p-Akt, Bcl-2, Bax, and cleaved caspase-3 3 days after IR injury. Figure 5 Part D in the middle is the quantitative analysis result of the protein levels of Dab1, p-Dab1, Pi3k, Akt, p-Akt, Bcl-2, Bax and cleaved caspase-3 in the retina after local knockdown of Reln 3 days after IR injury. The scale bar is 40 μm, and the data are expressed as mean ± standard deviation. *P<0.05, **P<0.01, ***P<0.001.

[0065] In the frozen sections of the retina of the non-IR-injured group, almost no TUNEL-positive cells were observed. However, 7 days after IR-injured, the number of TUNEL-positive cells in the mouse retina increased significantly, and the number of TUNEL-positive cells increased significantly after local knockdown of the Reln gene (see Figure 5 Part A and Part B, P < 0.05), indicating that Reln gene knockdown promotes cell apoptosis after IR injury. To further explore its mechanism, Western Blot experiments were performed on the samples based on the results of single-cell transcriptome analysis.

[0066] The specific operation is as follows: 3 days after I / R injury, the eyeballs were collected as described above and the retinas were isolated under a surgical microscope. The retina was fully lysed with RIPA lysis buffer (Radio Immunoprecipitation Assay Lysisbuffer) containing protease inhibitors and the total retinal protein was extracted from the lysed samples. The protein concentration was determined using a BCA protein assay kit (Promega, Madison, WI, USA). The protein samples were separated on 10% polyacrylamide gel electrophoresis, and then the proteins were transferred to nitrocellulose membranes using a transfer semi-dry system. After blocking with 5% skim milk for 0.5 h at room temperature, the membranes were incubated with primary antibodies: anti-phospho-Dab1 (ab78200; Abcam), anti-Dab1 (ab111684; Abcam), anti-Pi3k (ab302958; Abcam), anti-phospho-Akt (4060S; Cell Signaling Technology, Massachusetts, USA), anti-pan-Akt (ab8805; Abcam), anti-Bcl-2 (ab182858; Abcam), anti-Bax (ab32503; Abcam), anti-cleaved caspase-3 (9661S; Cell Signaling Technology), and anti-β-actin (66009-1, Proteintech, Rosemont, IL, USA). They were incubated overnight at 4°C and then incubated with HRP-conjugated secondary antibodies for 2 h at room temperature. The ChemiDoc TM Protein bands were photographed using the MP imaging system (Bio-Rad) and analyzed using ImageJ software (https: / / imagej.nih.gov / ij / ).

[0067] The results showed that there was no significant change in the expression level of AKT protein between the AAV-shReln-IR group and the AAV-EGFP-IR group, but the expression of phosphorylation-related proteins p-Akt and Pi3k in the AAV-shReln-IR group was significantly lower than that in the AAV-EGFP-IR group, and the expression of apoptosis-related protein Caspase-3 and the ratio of Bax / Bcl2 were significantly higher in the AAV-EGFP-IR group (see Figure 5In addition, there was no significant change in the expression level of Dab1 protein between the AAV-shReln-IR group and the AAV-EGFP-IR group, but the expression of p-Dab1 protein in the AAV-shReln-IR group was significantly lower than that in the AAV-EGFP-IR group. This shows that knockdown of the Reln gene leads to decreased phosphorylation of Dab1 protein after retinal IR injury, and can inhibit the activation of the Pi3k-Akt pathway, thereby promoting apoptosis of retinal cells after injury.

[0068] From the results of Example 2 to Example 4, it can be seen that after local knockdown of the Reln gene, the mouse retinal thickness becomes thinner, the number of RGC cells decreases, and the retinal dysfunction leads to further aggravation of retinal IR damage. And the knockdown of the Reln gene leads to reduced phosphorylation of Dab1 protein after retinal IR damage, and can inhibit the activation of the Pi3k-Akt pathway to promote retinal cell apoptosis after damage. In order to further confirm the potential therapeutic effect of Reelin protein in IR damage, Reelin protein was injected into the IR-damaged mouse model to explore its damage and repair effect on retinal tissue.

[0069] Example 5: Reelin protein promotes retinal tissue damage repair

[0070] In order to determine the potential therapeutic effect of Reelin protein in IR injury, exogenous recombinant Reelin protein was administered into the vitreous cavity 24 h before modeling, and PBS was injected into the vitreous cavity as a control group. The specific operation is referred to the operation in Example 1, which will not be repeated here. Then, the retina of mice 7 days after IR injury was used, and HE staining was performed to measure and count the thickness of the inner retinal layer. The results are referred to Figure 6 , Figure 6 This is a graph showing the results of Reelin protein promoting retinal tissue damage repair provided by an embodiment of the present invention. Figure 6 Part A in the middle is the result of HE staining retinal tissue pathology examination. Figure 6 Part B is a representative OCT image of retinal tissue showing the changes 7 days after IR injury. Figure 6 Part C in the middle is the distribution result of RBPMS-positive RGC (orange) in the retinal flat mount by epifluorescence staining 7 days after IR injury. Figure 6 Part D in the middle is a representative oscillatory potential waveform result of visual function evaluated by FERG 7 days after IR injury. Figure 5 Part E in the middle is the quantitative result of retinal thickness (n=6). Figure 6 Part F in the middle is the quantitative result of total retinal thickness (n=6). Figure 6 The middle G part shows the number of RBPMS-positive RGCs (n=4). Figure 6The middle H part is the quantitative results of a-wave and b-wave amplitude (n=6), the scale bar is 20 μm, 100 μm or 1 mm, and the data are expressed as mean ± standard deviation. *P<0.05, **P<0.01, ***P<0.001.

[0071] It can be seen that the thickness of the inner retina of the mice in the IR injury group was significantly lower than that of the uninjured group. The thickness of the inner retina of the mice was significantly reduced 7 days after IR injury, and this IR-induced thinning of the inner retina was significantly improved in mice given exogenous reelin protein (see Figure 6 Part A and Part E, P < 0.05). Afterwards, the inventors used OCT to evaluate the retinal tissue in vivo, and the results showed that Reelin protein also has a protective effect on the thickness of the entire retina after injury (see Figure 6 Part B and F in the middle, P < 0.05). Immunofluorescence staining of mouse retinas revealed that the number of RGCs in the mouse retina was significantly reduced compared with the uninjured group 7 days after IR injury. The supplementation of Reelin protein has a significant protective effect on RGCs after injury, as reflected in the fact that the RGC count in the Reelin-IR group was significantly increased compared with the PBS-IR group (see Figure 6 In addition, visual function was evaluated by FERG (flash electroretinogram, which is a group of potential changes recorded at the corneal end when retinal neurons are stimulated by light. Its waveform is the result of the joint action of multiple retinal neurons). The results showed that the amplitude of the retinal a wave or b wave of mice in the IR group was significantly decreased, while the amplitude of the retinal a wave or b wave of mice in the Reelin-IR group was significantly increased compared with that in the PBS-IR group (see Figure 6 (D and H, P < 0.05). Moreover, the b-wave amplitude of the Reelin group without IR injury was slightly increased compared with that of the PBS group, but there was no statistical difference. In summary, appropriate supplementation of Reelin protein can promote retinal tissue repair, which is reflected in reducing retinal thinning, RGC reduction and retinal dysfunction after IR injury. Therefore, Reelin protein can be used as a new injury repair intervention target for the treatment of retinal diseases.

[0072] Example 6: Reelin protein inhibits cell apoptosis via Dab1-Pi3k / Akt pathway

[0073] As described in Example 5, Reelin protein inhibited the death of mouse retinal RGCs after IR injury. In order to clarify the neuroprotective mechanism induced by Reelin protein, the effect of Reelin protein on cell apoptosis was evaluated by TUNEL staining. The results are shown in Figure 7 , Figure 7 This is a graph showing the results of Reelin protein inhibiting cell apoptosis through the Dab1-Pi3k / Akt pathway after retinal IR injury provided by an embodiment of the present invention, wherein: Figure 7 Part A in the middle is a representative TUNEL staining image of retinal frozen sections 3 days after IR injury. Figure 7 Part B is the quantification of TUNEL-positive cells (n=6). Figure 7 Part C in the middle is a representative blot showing the effects of Reelin protein treatment on retinal Dab1, p-Dab1, Pi3k, Akt, p-Akt, Bcl-2, Bax, and cleaved caspase-3 3 days after IR injury. Figure 7 Part D in the middle is the quantitative analysis result of the effect of Reelin protein treatment on the levels of retinal Dab1, p-Dab1, Pi3k, Akt, p-Akt, Bcl-2, Bax and cleaved caspase-3 proteins 3 days after IR injury. The scale bar is 40 μm. The data are expressed as mean ± standard deviation (n=3). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0074] In the frozen sections of the retina of the uninjured group, almost no TUNEL-positive cells were observed. However, 7 days after IR injury, the number of TUNEL-positive cells in the retina of mice increased significantly, and the number of TUNEL-positive cells in the Reelin-IR group decreased significantly (see Figure 7 Part A and Part B, P < 0.05), indicating that Reelin protein can effectively inhibit retinal cell apoptosis after injury. To further explore the anti-apoptotic mechanism of Reelin protein, Western Blot experiments were performed on the samples based on the results of single-cell transcriptome analysis. The results showed that there was no significant change in the expression level of AKT protein between the Reelin-IR group and the PBS-IR group, but the expression of phosphorylation-related proteins p-Akt and Pi3K in the Reelin-IR group was significantly higher than that in the PBS-IR group, while the expression of apoptosis-related protein Caspase-3 and the ratio of BAX / BCL2 were significantly lower than those in the PBS-IR group (see Figure 7 In the C and D parts of the middle, P < 0.05). In addition, there was no significant change in the expression level of Dab1 protein in the Reelin-IR group and the PBS-IR group, but the expression of phosphorylation-related protein p-Dab1 in the Reelin-IR group was significantly higher than that in the PBS-IR group. It can be seen that the supplementation of Reelin protein after retinal IR injury can cause the phosphorylation of Dab1 protein to play a biological role, and may inhibit the apoptosis of retinal cells after injury by activating the Pi3k-Akt pathway.

[0075] The embodiment of the present invention provides an application of Reelin protein in the preparation of a drug for treating retinal damage. The Reelin protein is used to prepare a drug for treating retinal damage, and the retinal ischemia-reperfusion injury process is regulated by improving abnormal retinal tissue morphology, retinal optic nerve cell death, retinal dysfunction and retinal cell apoptosis after retinal damage. The Reelin protein activates the Pi3k-Akt pathway to inhibit retinal cell apoptosis after damage by causing phosphorylation of Dab1 protein. The use of Reelin protein in the preparation of a drug for treating retinal damage can provide a basis for a new drug for treating retinal ischemia-reperfusion injury.

[0076] The above is a detailed introduction to the application of a Reelin protein provided by the present invention in the preparation of a drug for treating retinal damage. Specific examples are used herein to illustrate the principle and implementation mode of the present invention. The description of the above embodiments is only used to help understand the method of the present invention and its core idea. At the same time, for those skilled in the art, according to the idea of ​​the present invention, there will be changes in the specific implementation mode and application scope. In summary, the content of this specification should not be understood as limiting the present invention.

Claims

1. A method for preparing a drug for treating retinal damage.

2. The use according to claim 1, It is characterized in that The Reelin protein regulates the retinal ischemia-reperfusion injury process by improving the abnormal retinal tissue morphology after retinal injury.

3. The use according to claim 1, It is characterized in that The Reelin protein regulates the retinal ischemia-reperfusion injury process by improving retinal optic nerve cell death after retinal injury.

4. The use according to claim 1, It is characterized in that The Reelin protein regulates the retinal ischemia-reperfusion injury process by improving retinal dysfunction after retinal injury.

5. The use according to claim 1, It is characterized in that The Reelin protein regulates the process of retinal ischemia-reperfusion injury by improving retinal cell apoptosis after retinal injury.

6. The use according to claim 1, It is characterized in that The Reelin protein regulates the retinal ischemia-reperfusion injury process through the Dab1-Pi3k / Akt pathway.

7. The use according to claim 6, It is characterized in that The Reelin protein inhibits retinal cell apoptosis after injury by activating the Pi3k / Akt pathway through phosphorylation of the intracellular Dab1 protein.

8. A drug for treating retinal damage, It is characterized in that The active ingredient of the medicine is Reelin protein.

9. The drug according to claim 8, It is characterized in that The drug further comprises a pharmaceutically acceptable carrier, and the pharmaceutically acceptable carrier at least comprises physiological saline or PBS.

10. The drug according to claim 8, It is characterized in that The dosage range of the drug is 300ng / ul to 500ng / ul.

Citation Information

Patent Citations

  • Protective agent for retinal nerve or optic nerve

    CA2673751A1

  • Compositions and methods for treating retinal diseases

    CN103687626A

  • Application of Reelin protein or Reln gene in corneal injury treatment medicine

    CN117018165A